Precious Etinosa

Dr. Precious Etinosa

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SES. C. Eluu
S. C. Eluu
John David ObayemiJohn David Obayemi
John David Obayemi
ASAli A Salifu
Ali A Salifu
DYD. Yiporo
D. Yiporo
AOA. O. Oko
A. O. Oko
WSWinston Wole Soboyejo
Winston Wole Soboyejo
Triple-negative breast cancer (TNBC) treatment is challenging and frequently characterized by an aggressive phenotype and low prognosis in comparison to other subtypes. This paper presents fabricated implantable drug-loaded microporous poly-di-methyl-siloxane (PDMS) devices for the delivery of targeted therapeutic agents [Luteinizing Hormone-Releasing Hormone conjugated paclitaxel (PTX-LHRH) and Luteinizing Hormone-Releasing Hormone conjugated prodigiosin (PG-LHRH)] for the treatment and possible prevention of triple-negative cancer recurrence. In vitro assessment using the Alamar blue assay demonstrated a significant reduction (p < 0.05) in percentage of cell growth in a time-dependent manner in the groups treated with PG, PG-LHRH, PTX, and PTX-LHRH. Subcutaneous triple-negative xenograft breast tumors were then induced in athymic female nude mice that were four weeks old. Two weeks later, the tumors were surgically but partially removed, and the device implanted. Mice were observed for tumor regrowth and organ toxicity. The animal study revealed that there was no tumor regrowth, six weeks post-treatment, when the LHRH targeted drugs (LHRH-PTX and LHRH-PGS) were used for the treatment. The possible cytotoxic effects of the released drugs on the liver, kidney, and lung are assessed using quantitative biochemical assay from blood samples of the treatment groups. Ex vivo histopathological results from organ tissues showed that the targeted cancer drugs released from the implantable drug-loaded device did not induce any adverse effect on the liver, kidneys, or lungs, based on the results of qualitative toxicity studies. The implications of the results are discussed for the targeted and localized treatment of triple negative breast cancer.

11 April 2023 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
PEPrecious Etinosa
Precious Etinosa
ASAli A. Salifu
Ali A. Salifu
SASalifu T. Azeko
Salifu T. Azeko
JOJohn D. Obayemi
John D. Obayemi
EOEmmanuel O. Onche
Emmanuel O. Onche
WSWinston Wole Soboyejo
Winston Wole Soboyejo

20 December 2023 in Materials & Design
Verified
Journal Article
Open access
PEPrecious Etinosa
Precious Etinosa
ASAli A. Salifu
Ali A. Salifu
SOSarah Osafo
Sarah Osafo
SEStanley C. Eluu
Stanley C. Eluu
JOJohn D. Obayemi
John D. Obayemi
WSWinston O. Soboyejo
Winston O. Soboyejo


Verified
Journal Article
Open access
PDF file
SEStanley C. Eluu
Stanley C. Eluu
John David ObayemiJohn David Obayemi
John David Obayemi
YDYiporo Danyuo
Yiporo Danyuo
ASAli A. Salifu
Ali A. Salifu
AOAugustine O. Oko
Augustine O. Oko
WSWinston Wole Soboyejo
Winston Wole Soboyejo
This study presents LHRH conjugated drug delivery via a magnetite nanoparticle-modified microporous Poly-Di-Methyl-Siloxane (PDMS) system for the targeted suppression of triple-negative breast cancer cells. First, the MNP-modified PDMS devices are fabricated before loading with targeted and untargeted cancer drugs. The release kinetics from the devices are then studied before fitting the results to the Korsmeyer–Peppas model. Cell viability and cytotoxicity assessments are then presented using results from the Alamar blue assay. Apoptosis induction is then elucidated using flow cytometry. The in vitro drug release studies demonstrated a sustained and controlled release of unconjugated drugs (Prodigiosin and paclitaxel) and conjugated drugs [LHRH conjugated paclitaxel (PTX+LHRH) and LHRH-conjugated prodigiosin (PG+LHRH)] from the magnetite nanoparticle modified microporous PDMS devices for 30 days at 37 °C, 41 °C, and 44 °C. At 24, 48, 72, and 96 h, the groups loaded with conjugated drugs (PG+LHRH and PTX+LHRH) had a significantly higher (p < 0.05) percentage cell growth inhibition than the groups loaded with unconjugated drugs (PG and PTX). Additionally, throughout the study, the MNP+PDMS (without drug) group exhibited a steady rise in the percentage of cell growth inhibition. The flow cytometry results revealed a high incidence of early and late-stage apoptosis. The implications of the results are discussed for the development of biomedical devices for the localized and targeted release of cancer drugs that can prevent cancer recurrence following tumor resection.

17 April 2024 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
SOSarah Akua Osafo
Sarah Akua Osafo
PEPrecious Etinosa
Precious Etinosa
John David ObayemiJohn David Obayemi
John David Obayemi
ASAli A Salifu
Ali A Salifu
TATabiri Asumadu
Tabiri Asumadu
WSWinston Wole Soboyejo
Winston Wole Soboyejo